(Reuters) - Pfizer Inc ended an agreement with Pain Therapeutics Inc to develop and market Durect Corp's pain drug, Remoxy, sending the stocks of the two smaller drugmakers plummeting. Durect's shares fell as much as 46 percent in early trading on Monday, while Pain Therapeutics stock slumped 61 percent. Pain Therapeutics, which since 2002 has the license to develop and commercialize Remoxy, would now have to develop the drug on its own or find a new partner, Durect said in a statement. ...
via Health News Headlines - Yahoo News http://ift.tt/1rLsrx3
No comments:
Post a Comment